|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
Lung and Thoracic cancer
Intrathoracic Progression Is Still the Most Dominant Failure Pattern after First-Line Chemo-immunotherapy in Extensive-Stage
Small-Cell Lung Cancer
: Implications for Thoracic Radiotherapy
Dowook Kim, Hak Jae Kim, Hong-Gyun Wu, Joo Ho Lee, Suzy Kim, Tae Min Kim, Jin-Soo Kim, Byoung Hyuck Kim
Cancer Res Treat.
2024;56(2):430-441. Published online November 6, 2023 DOI:
https://doi.org/10.4143/crt.2023.931
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with
EGFR
-Mutant Non–Small Cell Lung Cancer
Hyun Ae Jung, Sehhoon Park, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
Cancer Res Treat.
2023;55(2):479-487. Published online December 27, 2022 DOI:
https://doi.org/10.4143/crt.2022.1344
Web of Science 3
Crossref 3
The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with
Small-Cell Lung Cancer
Yu Feng, Yutao Liu, Mingming Yuan, Guilan Dong, Hongxia Zhang, Tongmei Zhang, Lianpeng Chang, Xuefeng Xia, Lifeng Li, Haohua Zhu, Puyuan Xing, Hongyu Wang, Yuankai Shi, Zhijie Wang, Xingsheng Hu
Cancer Res Treat.
2022;54(3):753-766. Published online October 5, 2021 DOI:
https://doi.org/10.4143/crt.2021.905
Web of Science 3
Crossref 3
Combination of Gemcitabine and Cisplatin as First-Line Therapy in Advanced Non-
Small-Cell Lung Cancer
Nam-Su Lee, Jae-Ho Byun, Sang-Byung Bae, Chan-Kyu Kim, Kyu-Taeg Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park
Cancer Res Treat.
2004;36(3):173-177. Published online June 30, 2004 DOI:
https://doi.org/10.4143/crt.2004.36.3.173
Crossref 7
A Phase II Study of Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Non-
small-cell Lung Cancer
Jung Ae Lee, Keun Seok Lee, Jin Seok Ahn, Jae Ho Byun, Hun Ho Song, Dae Young Zang, Young Iee Park, Young Suk Park, Eun Kyung Mo, Dong Kyu Kim, Myung Goo Lee, In Gyu Hyun, Ki Suck Jung, Soo Mee Bang, Gye Young Park, Jeong Woong Park, Eun Kyung Cho, Seong Hwan Jeong, Dong Bok Shin, Jae Hoon Lee
Cancer Res Treat.
2003;35(3):239-244. Published online June 30, 2003 DOI:
https://doi.org/10.4143/crt.2003.35.3.239
Crossref 1
Combination Chemotherapy with Cisplatin and Vinorelbine in Patients with Non-
Small-Cell Lung Cancer
Kee Won Kim, Suk Young Park, Ji Won Suhr, Seung Joon Kim, Dong Hoen Yang, Eun Hee Lee, Kyung Shick Lee
J Korean Cancer Assoc.
2000;32(5):911-917.
Combination Chemotherapy with VP - 16 , Ifosfamide , and Cisplatin ( VIP ) in the Advanced Non - Small Cell Lung Cancer
Yong Seon Cho, Si Young Kim, Jeong Hee Kim, Hwi Joong Yoon, Kyung Sam Cho
J Korean Cancer Assoc.
2000;32(1):86-92.
Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab After Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Insights from Real-World Data
Jeong Yun Jang, Si Yeol Song, Young Seob Shin, Ha Un Kim, Eun Kyung Choi, Sang-We Kim, Jae Cheol Lee, Dae Ho Lee, Chang-Min Choi, Shinkyo Yoon, Su Ssan Kim
Received September 6, 2023 Accepted January 14, 2024 Published online January 16, 2024
DOI:
https://doi.org/10.4143/crt.2023.1014
[Accepted]
Comparison of Clinicopathogenomic Features and Treatment Outcomes of
EGFR
and
HER2
Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer; Single-Institution Experience
So Heun Lee, Hyehyun Jeong, Deok Hoon Kim, Se Jin Jang, Sang-We Kim, Shinkyo Yoon, Dae Ho Lee
Received November 1, 2023 Accepted January 28, 2024 Published online January 30, 2024
DOI:
https://doi.org/10.4143/crt.2023.1177
[Accepted]
1
Journal Impact Factor 4.6